Clinical trial · Interventional
Fluciclovine (Axumin) PET/CT vs. NaF PET/CT in Prostate Cancer Osseous Metastatic Disease
[F-18] Fluciclovine (Axumin) PET/CT vs. [F-18] NaF PET/CT in the Evaluation of Prostate Cancer Osseous Metastatic Disease
NCT04765423CI-TRIAL-00057499withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor patient accrual
Summary
Brief summary (as posted)
The purpose of this study is to look at whether F-18 Fluciclovine (i.e. Axumin) is better or as good as F-18 Sodium Fluoride (F-18 NaF) when looking at bone disease from prostate cancer. Axumin is a radioactive agent used on a positron/computed tomography (PET/CT) camera to look for prostate cancer in general.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Neoplasm of Prostate | Malignant Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [F-18] fluciclovine PET/CT | Device | — | UNRESOLVED |
| [F-18] NaF PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- NaF PET/CT scan and F-18 fluciclovine PET/CT
- description
- Visit 1: Participant receives a whole body \[F-18\] NaF PET/CT (diagnostic study) Visit 2: Participant receives a whole body \[F-18\] fluciclovine PET/CT within 3 weeks of Visit 1
- interventionNames
- Device: [F-18] NaF PET/CT
- Device: [F-18] fluciclovine PET/CT
Primary outcomes (6)
- measure
- Number of lesions seen by [F-18] NaF PET/CT which are also seen by [F-18] fluciclovine PET/CT
- timeFrame
- At time of scan, up to 60 minutes per scan
- description
- Agreement of imaging methods as measured by number of lesions seen by \[F-18\] NaF PET/CT which are also seen by \[F-18\] fluciclovine PET/CT broken down by diagnostic score on a lesion-by-lesion basis (1 to 5) 1. Definitely benign 2. Probably benign 3. Equivocal 4. Probably malignant 5. Definitely malignant
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Referred for initial staging or restaging of prostate cancers with clinical suspicion of bone metastases. * Must understand and voluntarily sign an Informed Consent Document Exclusion Criteria: -Cannot tolerate imaging up to 60 minutes of total imaging
References
Publications (0)
Data not yet available
No reference posted for this study.